{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:27:29Z","timestamp":1789421249689,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-98771-w","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:29:32Z","timestamp":1746278972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds"],"prefix":"10.1038","volume":"15","author":[{"given":"Pardis","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab","family":"Najafipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amin","family":"Kouhpayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Farjadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmaeil","family":"Behmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"98771_CR1","doi-asserted-by":"publisher","first-page":"109545","DOI":"10.1016\/j.intimp.2022.109545","volume":"114","author":"C Dai","year":"2023","unstructured":"Dai, C., Huang, Y. H. & Jiang, M. Combination therapy in inflammatory bowel disease: current evidence and perspectives. Int. Immunopharmacol. 114, 109545 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"98771_CR2","doi-asserted-by":"publisher","first-page":"111238","DOI":"10.1016\/j.intimp.2023.111238","volume":"126","author":"X Cui","year":"2024","unstructured":"Cui, X. et al. Therapeutic potential of a synthetic dual JAK1\/TYK2 inhibitor in inflammatory bowel disease. Int. Immunopharmacol. 126, 111238 (2024).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"98771_CR3","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1038\/s41598-024-55869-x","volume":"14","author":"G Xu","year":"2024","unstructured":"Xu, G., Xu, Y., Zheng, T. & Liu, T. Type 2 diabetes and inflammatory bowel disease: a bidirectional two-sample Mendelian randomization study. Sci. Rep. 14 (1), 5149 (2024).","journal-title":"Sci. Rep."},{"issue":"3","key":"98771_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/life13030680","volume":"13","author":"R Kaddoura","year":"2023","unstructured":"Kaddoura, R. et al. Identification of specific biomarkers and pathways in the treatment response of Infliximab for inflammatory bowel disease: in-silico analysis. Life 13 (3), 680 (2023).","journal-title":"Life"},{"issue":"2","key":"98771_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/jcm12020641","volume":"12","author":"GP Caviglia","year":"2023","unstructured":"Caviglia, G. P. et al. Epidemiology of inflammatory bowel diseases: a population study in a healthcare district of North-West Italy. J. Clin. Med. 12 (2), 641 (2023).","journal-title":"J. Clin. Med."},{"key":"98771_CR6","doi-asserted-by":"publisher","first-page":"107778","DOI":"10.1016\/j.compbiomed.2023.107778","volume":"168","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Biomarkers prediction and immune landscape in ulcerative colitis: findings based on bioinformatics and machine learning. Comput. Biol. Med. 168, 107778 (2024).","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"98771_CR7","doi-asserted-by":"publisher","first-page":"14977","DOI":"10.1038\/s41598-020-71939-2","volume":"10","author":"S Vaga","year":"2020","unstructured":"Vaga, S. et al. Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. Sci. Rep. 10 (1), 14977 (2020).","journal-title":"Sci. Rep."},{"key":"98771_CR8","doi-asserted-by":"crossref","unstructured":"Chang, J. T. Pathophysiology of inflammatory bowel diseases. Longo DL, editor. N. Engl. J. Med. 383(27), 2652\u20132664 (2020).","DOI":"10.1056\/NEJMra2002697"},{"key":"98771_CR9","doi-asserted-by":"publisher","first-page":"1065608","DOI":"10.3389\/fmicb.2022.1065608","volume":"13","author":"B Liang","year":"2022","unstructured":"Liang, B. et al. New insights into bacterial mechanisms and potential intestinal epithelial cell therapeutic targets of inflammatory bowel disease. Front. Microbiol. 13, 1065608 (2022).","journal-title":"Front. Microbiol."},{"issue":"4","key":"98771_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","volume":"50","author":"M Friedrich","year":"2019","unstructured":"Friedrich, M., Pohin, M. & Powrie, F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity 50 (4), 992\u20131006 (2019).","journal-title":"Immunity"},{"issue":"1","key":"98771_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee, S. H., Kwon, J. E. & Cho, M. L. Immunological pathogenesis of inflammatory bowel disease. Intest. Res. 16 (1), 26 (2018).","journal-title":"Intest. Res."},{"issue":"Supplement_2","key":"98771_CR12","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","volume":"16","author":"GW Sewell","year":"2022","unstructured":"Sewell, G. W. & Kaser, A. Interleukin-23 in the pathogenesis of inflammatory bowel disease and implications for therapeutic intervention. J. Crohn\u2019s Colitis. 16 (Supplement_2), ii3\u201319 (2022).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"98771_CR13","doi-asserted-by":"publisher","first-page":"368738","DOI":"10.3389\/fimmu.2018.01270","volume":"9","author":"C Andrews","year":"2018","unstructured":"Andrews, C., McLean, M. H. & Durum, S. K. Cytokine tuning of intestinal epithelial function. Front. Immunol. 9, 368738 (2018).","journal-title":"Front. Immunol."},{"key":"98771_CR14","doi-asserted-by":"crossref","unstructured":"Makhoba, X. H., Viegas, C. Jr, Mosa, R. A., Viegas, F. P. & Pooe, O. J. Potential impact of the multi-target drug approach in the treatment of some complex diseases. Drug Des. Dev. Ther. 3235\u20133249 (2020).","DOI":"10.2147\/DDDT.S257494"},{"key":"98771_CR15","doi-asserted-by":"publisher","first-page":"730257","DOI":"10.3389\/fphar.2021.730257","volume":"12","author":"W L\u00f6scher","year":"2021","unstructured":"L\u00f6scher, W. Single-target versus multi-target drugs versus combinations of drugs with multiple targets: preclinical and clinical evidence for the treatment or prevention of epilepsy. Front. Pharmacol. 12, 730257 (2021).","journal-title":"Front. Pharmacol."},{"issue":"15","key":"98771_CR16","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.3390\/molecules27154964","volume":"27","author":"L Crocetti","year":"2022","unstructured":"Crocetti, L., Floresta, G., Cilibrizzi, A. & Giovannoni, M. P. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules 27 (15), 4964 (2022).","journal-title":"Molecules"},{"issue":"1","key":"98771_CR17","doi-asserted-by":"publisher","first-page":"19737","DOI":"10.1038\/s41598-021-98743-w","volume":"11","author":"XL Dong","year":"2021","unstructured":"Dong, X. L., Wang, Y. H., Xu, J. & Zhang, N. The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP\/AMPK\/SIRT1 pathway. Sci. Rep. 11 (1), 19737 (2021).","journal-title":"Sci. Rep."},{"key":"98771_CR18","unstructured":"https:\/\/www.amgen.com\/newsroom\/press-releases\/2019\/08\/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits [Internet]. [cited 2024 Apr 14]."},{"issue":"11","key":"98771_CR19","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","volume":"18","author":"S Danese","year":"2020","unstructured":"Danese, S. et al. Effects of Apremilast, an oral inhibitor of phosphodiesterase 4, in a randomized trial of patients with active ulcerative colitis. Clin. Gastroenterol. Hepatol. 18 (11), 2526\u20132534 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"98771_CR20","unstructured":"Otsuka, P. D. & Commercialization, Inc. FACTS II: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-arm study of the efficacy and safety of OPC-6535 tablets in the treatment of subjects with active ulcerative colitis [Internet]. clinicaltrials.gov; 2012 May [cited 2024 Jan 1]. Report No.: NCT00064454. https:\/\/clinicaltrials.gov\/study\/NCT00064454."},{"key":"98771_CR21","unstructured":"Otsuka Pharmaceutical, D., Commercialization, I. P. & Double-Blind, M. C. R. 3, Parallel-Arm, 52-week dose comparison study of the efficacy and safety of 25\u00a0mg QD and 50\u00a0mg QD of OPC-6335 oral tablets and 800\u00a0mg BID of Asacol\u00ae in the maintenance of ulcerative colitis remission [Internet]. clinicaltrials.gov; 2007 Jun [cited 2024 Jan 1]. Report No.: NCT00092508. https:\/\/clinicaltrials.gov\/study\/NCT00092508."},{"issue":"6","key":"98771_CR22","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1053\/j.gastro.2010.06.068","volume":"139","author":"MM Tambuwala","year":"2010","unstructured":"Tambuwala, M. M. et al. Loss of Prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139 (6), 2093\u20132101 (2010).","journal-title":"Gastroenterology"},{"issue":"12","key":"98771_CR23","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1161\/ATVBAHA.109.196071","volume":"29","author":"K Takeda","year":"2009","unstructured":"Takeda, K. et al. Inhibition of Prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-\u03b1 expression. Arterioscler. Thromb. Vasc. Biol. 29 (12), 2132\u20132137 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"98771_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola, P. E., Spinowitz, B. S., Hartman, C. S., Maroni, B. J. & Haase, V. H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 90 (5), 1115\u20131122 (2016).","journal-title":"Kidney Int."},{"key":"98771_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3389\/fmed.2020.00393","volume":"7","author":"Z Yan","year":"2020","unstructured":"Yan, Z. & Xu, G. A novel choice to correct inflammation-induced anemia in CKD: oral hypoxia-inducible factor Prolyl hydroxylase inhibitor Roxadustat. Front. Med. 7, 393 (2020).","journal-title":"Front. Med."},{"issue":"6","key":"98771_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"RA Brigandi","year":"2016","unstructured":"Brigandi, R. A. et al. A novel hypoxia-inducible factor\u2009\u2013\u2009prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am. J. Kidney Dis. 67 (6), 861\u2013871 (2016).","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"98771_CR27","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.4049\/jimmunol.1103817","volume":"189","author":"JM Roda","year":"2012","unstructured":"Roda, J. M. et al. Stabilization of HIF-2\u03b1 induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J. Immunol. 189 (6), 3168\u20133177 (2012).","journal-title":"J. Immunol."},{"issue":"1","key":"98771_CR28","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1038\/s41598-024-53945-w","volume":"14","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Prolyl hydroxylase domain inhibitor is an effective pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock. Sci. Rep. 14 (1), 3874 (2024).","journal-title":"Sci. Rep."},{"key":"98771_CR29","unstructured":"Aerpio Therapeutics. Phase 1a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AKB 4924 in Healthy Male Volunteers [Internet]. clinicaltrials.gov; 2017 Mar [cited 2024 Jan 1]. Report No.: NCT02914262. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02914262"},{"key":"98771_CR30","doi-asserted-by":"publisher","unstructured":"Fu, Y. et al. Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02503-w (2024).","DOI":"10.1038\/s41587-024-02503-w"},{"key":"98771_CR31","doi-asserted-by":"publisher","first-page":"112422","DOI":"10.1016\/j.intimp.2024.112422","volume":"137","author":"Z Qin","year":"2024","unstructured":"Qin, Z., Tang, R., Liang, J. & Jia, X. Berberine, a natural alkaloid: advances in its pharmacological effects and mechanisms in the treatment of autoimmune diseases. Int. Immunopharmacol. 137, 112422 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"98771_CR32","unstructured":"Herbal Medicine Market Size, Share, G., Analysis, B. & Form Application, Product Type, Source, Distribution Channel-Industry Forecast 2022\u20132028 [Internet]. [cited 2024 Apr 23]. https:\/\/www.skyquestt.com\/report\/herbal-medicine-market."},{"key":"98771_CR33","doi-asserted-by":"crossref","unstructured":"Peng, Y. et al. Anti-inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures. Drug Des. Dev. Ther. 4503\u20134525 (2021).","DOI":"10.2147\/DDDT.S327378"},{"issue":"7","key":"98771_CR34","doi-asserted-by":"publisher","first-page":"e0271045","DOI":"10.1371\/journal.pone.0271045","volume":"17","author":"B Das","year":"2022","unstructured":"Das, B. et al. The effect of a fennel seed extract on the STAT signaling and intestinal barrier function. PLoS One. 17 (7), e0271045 (2022).","journal-title":"PLoS One"},{"issue":"11","key":"98771_CR35","doi-asserted-by":"publisher","first-page":"9201","DOI":"10.3390\/ijms24119201","volume":"24","author":"E Lonati","year":"2023","unstructured":"Lonati, E. et al. Digested cinnamon (Cinnamomum verum J. Presl) bark extract modulates claudin-2 gene expression and protein levels under TNF\u03b1\/IL-1\u03b2 inflammatory stimulus. Int. J. Mol. Sci. 24 (11), 9201 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"98771_CR36","doi-asserted-by":"publisher","first-page":"104851","DOI":"10.1016\/j.compbiomed.2021.104851","volume":"137","author":"B Shaker","year":"2021","unstructured":"Shaker, B., Ahmad, S., Lee, J., Jung, C. & Na, D. Silico methods and tools for drug discovery. Comput. Biol. Med. 137, 104851 (2021).","journal-title":"Comput. Biol. Med."},{"key":"98771_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-015-0771-6","volume":"17","author":"M Perez-Aso","year":"2015","unstructured":"Perez-Aso, M. et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res. Ther. 17, 1\u201313 (2015).","journal-title":"Arthritis Res. Ther."},{"issue":"13","key":"98771_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. Vadadustat: first approval. Drugs 80 (13), 1365\u20131371 (2020).","journal-title":"Drugs"},{"issue":"12","key":"98771_CR39","doi-asserted-by":"publisher","first-page":"e1004586","DOI":"10.1371\/journal.pcbi.1004586","volume":"11","author":"PA Ravindranath","year":"2015","unstructured":"Ravindranath, P. A., Forli, S., Goodsell, D. S., Olson, A. J. & Sanner, M. F. AutoDockFR: advances in protein-ligand Docking with explicitly specified binding site flexibility. PLoS Comput. Biol. 11 (12), e1004586 (2015).","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"98771_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"issue":"9","key":"98771_CR41","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DE Pires","year":"2015","unstructured":"Pires, D. E., Blundell, T. L. & Ascher, D. B. PkCSM: predicting small-molecule Pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58 (9), 4066\u20134072 (2015).","journal-title":"J. Med. Chem."},{"key":"98771_CR42","unstructured":"Sander, T. Actelion\u2019s Property Explorer (Actelion\u2019s Pharmaceuticals Ltd: Allschwil, 2001)."},{"key":"98771_CR43","doi-asserted-by":"publisher","first-page":"108345","DOI":"10.1016\/j.jmgm.2022.108345","volume":"118","author":"E Behmard","year":"2023","unstructured":"Behmard, E. et al. Advanced simulations and screening to repurposing a 3\u00a0C protease inhibitor against the rupintrivir-resistant human norovirus-induced gastroenteritis. J. Mol. Graph. Model. 118, 108345 (2023).","journal-title":"J. Mol. Graph. Model."},{"key":"98771_CR44","doi-asserted-by":"publisher","first-page":"105709","DOI":"10.1016\/j.compbiomed.2022.105709","volume":"147","author":"M Ebrahimi","year":"2022","unstructured":"Ebrahimi, M., Karami, L. & Alijanianzadeh, M. Computational repurposing approach for targeting the critical Spike mutations in B. 1.617. 2 (delta), AY. 1 (delta plus) and C. 37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods. Comput. Biol. Med. 147, 105709 (2022).","journal-title":"Comput. Biol. Med."},{"key":"98771_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"98771_CR46","doi-asserted-by":"crossref","unstructured":"Hess, B., van der Spoel, D., Abraham, M. J. & Lindahl, E. On the importance of accurate algorithms for reliable molecular dynamics simulations. (2019).","DOI":"10.26434\/chemrxiv.11474583.v1"},{"issue":"12","key":"98771_CR47","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1021\/acs.jcim.5b00308","volume":"55","author":"MD Smith","year":"2015","unstructured":"Smith, M. D., Rao, J. S., Segelken, E. & Cruz, L. Force-field induced bias in the structure of A\u03b221\u201330: A comparison of OPLS, AMBER, CHARMM, and GROMOS force fields. J. Chem. Inf. Model. 55 (12), 2587\u20132595 (2015).","journal-title":"J. Chem. Inf. Model."},{"issue":"43","key":"98771_CR48","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"P Mark","year":"2001","unstructured":"Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K. J. Phys. Chem. A. 105 (43), 9954\u20139960 (2001).","journal-title":"J. Phys. Chem. A"},{"issue":"19","key":"98771_CR49","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103 (19), 8577\u20138593 (1995).","journal-title":"J. Chem. Phys."},{"issue":"12","key":"98771_CR50","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess, B., Bekker, H., Berendsen, H. J. & Fraaije, J. G. LINCS: a linear constraint solver for molecular simulations. J. Comput. Chem. 18 (12), 1463\u20131472 (1997).","journal-title":"J. Comput. Chem."},{"issue":"12","key":"98771_CR51","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1021\/acs.jcim.7b00564","volume":"57","author":"Z Cournia","year":"2017","unstructured":"Cournia, Z., Allen, B. & Sherman, W. Relative binding free energy calculations in drug discovery: recent advances and practical considerations. J. Chem. Inf. Model. 57 (12), 2911\u20132937 (2017).","journal-title":"J. Chem. Inf. Model."},{"key":"98771_CR52","doi-asserted-by":"publisher","first-page":"104817","DOI":"10.1016\/j.compbiomed.2021.104817","volume":"137","author":"LB Federico","year":"2021","unstructured":"Federico, L. B. et al. Potential Colchicine binding site inhibitors unraveled by virtual screening, molecular dynamics and MM\/PBSA. Comput. Biol. Med. 137, 104817 (2021).","journal-title":"Comput. Biol. Med."},{"key":"98771_CR53","doi-asserted-by":"publisher","first-page":"113544","DOI":"10.1016\/j.intimp.2024.113544","volume":"144","author":"P Mansouri","year":"2025","unstructured":"Mansouri, P. et al. Novel targets for mucosal healing in inflammatory bowel disease therapy. Int. Immunopharmacol. 144, 113544 (2025).","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"98771_CR54","doi-asserted-by":"publisher","first-page":"e0305934","DOI":"10.1371\/journal.pone.0305934","volume":"19","author":"AR Alanzi","year":"2024","unstructured":"Alanzi, A. R., Alsalhi, M. S., Mothana, R. A., Alqahtani, J. H. & Alqahtani, M. J. Insilico discovery of novel phosphodiesterase 4 (PDE4) inhibitors for the treatment of psoriasis: insights from computer aided drug design approaches. PLoS One. 19 (11), e0305934 (2024).","journal-title":"PLoS One"},{"key":"98771_CR55","doi-asserted-by":"crossref","unstructured":"Al-Nema, M., Gaurav, A. & Lee, V. S. Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor. Heliyon. 6(9). (2020).","DOI":"10.1016\/j.heliyon.2020.e04856"},{"key":"98771_CR56","doi-asserted-by":"publisher","first-page":"113004","DOI":"10.1016\/j.biopha.2022.113004","volume":"150","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. A novel PHD2 inhibitor acteoside from Cistanche tubulosa induces skeletal muscle mitophagy to improve cancer-related fatigue. Biomed. Pharmacother. 150, 113004 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"98771_CR57","doi-asserted-by":"publisher","first-page":"1351737","DOI":"10.3389\/fcimb.2024.1351737","volume":"14","author":"CN Ashley","year":"2024","unstructured":"Ashley, C. N. et al. Identifying potential Monkeypox virus inhibitors: an in Silico study targeting the A42R protein. Front. Cell. Infect. Microbiol. 14, 1351737 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"98771_CR58","first-page":"185","volume":"67","author":"R Kusumawati","year":"2018","unstructured":"Kusumawati, R., Sulastomo, H., Setyawan, A. N. & Dewi, R. Sojagol from mung beans as A potential antagonist of mineralocorticoid receptor. Hiroshima J. Med. Sci. 67, 185\u2013190 (2018).","journal-title":"Hiroshima J. Med. Sci."},{"issue":"9","key":"98771_CR59","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/jgh.14581","volume":"34","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Antitumor activity in colorectal cancer induced by Hinokiflavone. J. Gastroenterol. Hepatol. 34 (9), 1571\u20131580 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"98771_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/cbf.3443","volume":"38","author":"W Huang","year":"2020","unstructured":"Huang, W. et al. Hinokiflavone induces apoptosis and inhibits migration of breast cancer cells via EMT signalling pathway. Cell Biochem. Funct. 38 (3), 249\u2013256 (2020).","journal-title":"Cell Biochem. Funct."},{"key":"98771_CR61","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.fct.2013.04.028","volume":"58","author":"KS Suh","year":"2013","unstructured":"Suh, K. S., Lee, Y. S., Kim, Y. S. & Choi, E. M. Sciadopitysin protects osteoblast function via its antioxidant activity in MC3T3-E1 cells. Food Chem. Toxicol. 58, 220\u2013227 (2013).","journal-title":"Food Chem. Toxicol."},{"key":"98771_CR62","doi-asserted-by":"publisher","first-page":"111642","DOI":"10.1016\/j.fct.2020.111642","volume":"145","author":"M Adnan","year":"2020","unstructured":"Adnan, M. et al. Ginkgetin: A natural biflavone with versatile pharmacological activities. Food Chem. Toxicol. 145, 111642 (2020).","journal-title":"Food Chem. Toxicol."},{"key":"98771_CR63","doi-asserted-by":"publisher","first-page":"154846","DOI":"10.1016\/j.phymed.2023.154846","volume":"116","author":"L Wu","year":"2023","unstructured":"Wu, L. et al. Ginkgetin suppresses ovarian cancer growth through Inhibition of JAK2\/STAT3 and MAPKs signaling pathways. Phytomedicine. 116, 154846 (2023).","journal-title":"Phytomedicine"},{"key":"98771_CR64","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.tice.2022.101967","volume":"79","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Niu, Y. & Weng, Q. Ginkgetin promotes proliferation and migration of Schwann cells via PIGF\/p38 MAPK signaling pathway. Tissue Cell. 79, 101967 (2022).","journal-title":"Tissue Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98771-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98771-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98771-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T15:02:53Z","timestamp":1746284573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98771-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98771-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15542"}}